Characterization and lineage tracing of a mouse adipose depot reveal properties conserved with human supraclavicular brown adipose tissue

  • 0Department of Pediatrics, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA 94158, USA; Department of Pediatrics, Yale School of Medicine, New Haven, CT 06520, USA.

|

|

Summary

This summary is machine-generated.

Researchers identified a distinct mouse beige fat depot with developmental origins and features mirroring human brown fat. This discovery offers a valuable preclinical model for metabolic disorder therapies.

Area Of Science

  • Metabolic disorders
  • Adipose tissue biology
  • Therapeutic development

Background

  • Beige adipocytes enhance energy expenditure, offering therapeutic potential for metabolic disorders.
  • Understanding beige fat origins is crucial for developing effective preclinical models.
  • Current knowledge gaps hinder the translation of beige fat therapies.

Purpose Of The Study

  • To identify and characterize a distinct mouse beige adipose tissue (ibAT) depot.
  • To compare the developmental origins and characteristics of ibAT with human beige and brown adipose tissue.
  • To establish a relevant preclinical model for human beige adipose tissue.

Main Methods

  • Comparative lineage tracing using Prx1+ cells.
  • Morphological and molecular analysis of adipose tissue depots.
  • Assessment of thermogenic activity and aging capabilities.

Main Results

  • A distinct ibAT depot shares developmental origins (Prx1+ cells) with inguinal white adipose tissue (iWAT).
  • ibAT exhibits higher thermogenic activity and capability during aging compared to iWAT.
  • ibAT displays morphological, molecular, and developmental similarities to human supraclavicular brown adipose tissue (scBAT).

Conclusions

  • A novel mouse beige adipose tissue depot has been identified.
  • This ibAT depot serves as a preclinical model for human beige adipose tissue.
  • Findings advance understanding of beige fat development and maintenance for metabolic disease therapies.